Physician profile
Ryan Boer
NPI 1598162075
$3,457.90
in general payments reported to CMS, 2019-2025
24 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $117 · 2021: $87.59 · 2022: $449 · 2023: $897 · 2024: $902 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $861.38 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $714.73 | 2019-2025 | Tavneos, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $317.03 | 2019-2024 | Verquvo, Segluromet, Januvia |
| Glaxosmithkline, LLC. | $299.29 | 2019-2024 | Arexvy, Trelegy Ellipta, Bexsero |
| Abbvie INC. | $275.94 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $272.15 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Sanofi Pasteur INC. | $97.15 | 2019-2024 | |
| Corcept Therapeutics | $90.52 | 2024 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.32 | 2025 | Caplyta |
| Astellas Pharma US INC | $66.81 | 2023-2025 | Veozah |
| Pfizer INC. | $49.37 | 2022-2025 | |
| Novo Nordisk INC | $48.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $46.79 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $42.45 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $30.68 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.64 | 2023-2024 | |
| Exact Sciences Corporation | $30.13 | 2023 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $23.78 | 2024 | Daybue |
| Ultragenyx Pharmaceutical INC. | $19.49 | 2024 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.49 | 2023 | Rexulti |
| Allergan, INC. | $14.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Boer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.